Phase 1 Study of Oral TP-1454
Completed · Phase 1 · NCT04328740
Conditions: Advanced Solid Tumor, Anal Cancer
At a glance
- Research payments reported, 2025
- $89,237
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 31
About the trial
- Sponsor
- Sumitomo Pharma America, Inc.
- Tested
- TP-1454 monotherapy (drug)
- Dates
- Started 2020-07-08; completion 2025-04-25
- Results posted
- Not yet
This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.
From ClinicalTrials.gov, last updated 2025-05-01. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sumitomo Pharma America, Inc. reported $89,237 in research payments for this study in 2025 (18 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Thai H. Ho, M.D./PH.D. Hematology & Oncology · Scottsdale, AZ
- Anthony B. El-khoueiry, M.D. Medical Oncology · Los Angeles, CA
- Edwin C. Kingsley, MD Hematology & Oncology · Las Vegas, NV
- Cathy Eng, M.D. Medical Oncology · Nashville, TN
- Meredith S. Pelster, M.D. Hematology & Oncology · Nashville, TN
- Van K. Morris II, MD Hematology & Oncology · Houston, TX
- Ariel A. Nelson, M.D. Hematology & Oncology · Madison, WI
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Comprehensive Cancer Centers of Neveda $27,912
- Vanderbilt University Medical Center, TN $22,366
- Medical College of Wisconsin $15,513
- Ut MD Anderson Cancer Center $14,060
- University of Southern California $6,089
- Sarah Cannon Research Institute LLC $1,850
- Mayo Clinic Hospital, AZ $1,448
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.